MiNK Therapeutics Management
Management criteria checks 2/4
MiNK Therapeutics' CEO is Jen Buell, appointed in Feb 2021, has a tenure of 3.17 years. total yearly compensation is $3.87M, comprised of 11% salary and 89% bonuses, including company stock and options. directly owns 0.67% of the company’s shares, worth $207.56K. The average tenure of the management team and the board of directors is 2.7 years and 5 years respectively.
Key information
Jen Buell
Chief executive officer
US$3.9m
Total compensation
| CEO salary percentage | 11.0% |
| CEO tenure | 3.2yrs |
| CEO ownership | 0.7% |
| Management average tenure | 2.7yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
MiNK Therapeutics (NASDAQ:INKT) Will Have To Spend Its Cash Wisely
Oct 26
Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?
Jun 28Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Invest In Growth?
Mar 18MiNK Therapeutics GAAP EPS of -$0.18
Aug 16MiNK Therapeutics GAAP EPS of -$0.18
Aug 09MiNK Therapeutics A Bargain For Potential Cell Therapies
Jun 23We're Hopeful That MiNK Therapeutics (NASDAQ:INKT) Will Use Its Cash Wisely
May 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$22m |
| Sep 30 2023 | n/a | n/a | -US$25m |
| Jun 30 2023 | n/a | n/a | -US$26m |
| Mar 31 2023 | n/a | n/a | -US$26m |
| Dec 31 2022 | US$4m | US$424k | -US$28m |
| Sep 30 2022 | n/a | n/a | -US$26m |
| Jun 30 2022 | n/a | n/a | -US$34m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$3m | US$233k | -US$30m |
| Sep 30 2021 | n/a | n/a | -US$26m |
| Jun 30 2021 | n/a | n/a | -US$18m |
| Mar 31 2021 | n/a | n/a | -US$16m |
| Dec 31 2020 | US$917 | n/a | -US$16m |
Compensation vs Market: Jen's total compensation ($USD3.87M) is above average for companies of similar size in the US market ($USD677.87K).
Compensation vs Earnings: Jen's compensation has increased whilst the company is unprofitable.
CEO
Jen Buell (47 yo)
3.2yrs
Tenure
US$3,871,880
Compensation
Dr. Jennifer S. Buell, also known as Jen, Ph.D. has been Independent Director at Protagenic Therapeutics, Inc. since July 18, 2020. Dr. Buell served as Chairman of the Board at MiNK Therapeutics, Inc. She...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 6.8yrs | no data | 4.98% $ 1.5m | |
| President | 3.2yrs | US$3.87m | 0.67% $ 207.6k | |
| Chief Scientific Officer | 2.1yrs | US$651.17k | 0.079% $ 24.5k | |
| Treasurer | 6.8yrs | US$27.24k | 0.16% $ 49.8k | |
| Vice President & Head of CMC | 2.3yrs | no data | no data |
2.7yrs
Average Tenure
59yo
Average Age
Experienced Management: INKT's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 6.8yrs | no data | 4.98% $ 1.5m | |
| President | 3.2yrs | US$3.87m | 0.67% $ 207.6k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.8yrs | US$84.80k | 1.02% $ 315.4k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.8yrs | US$119.50k | 1.0% $ 310.0k | |
| Independent Director | 2.6yrs | US$119.00k | 0.20% $ 60.7k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3yrs | US$90.30k | 0.17% $ 52.6k | |
| Member of the Scientific Advisory Board | no data | no data | no data |
5.0yrs
Average Tenure
63yo
Average Age
Experienced Board: INKT's board of directors are considered experienced (5 years average tenure).